Laparoscopic Partial Nephrectomy for cT1 Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

292 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-03-15

Study Completion Date

2019-11-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to evaluate trifecta and pentafecta outcomes for laparoscopic partial nephrectomy (LNP) in patients with clinical T1N0M0 renal tumor.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Current Role of Pentafecta Outcomes in Open and Laparoscopic Partial Nephrectomy for Localized Renal Tumors

NCT06969131

Pentafecta Laparoscopic Partial Nephrectomy +1 more

COMPLETED NA

Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Middle or Upper Third Gastric Cancer

NCT02333721

Stomach Neoplasms

UNKNOWN NA

Oncological and Functional Outcomes of Laparoscopic Partial Nephrectomy in Renal Cell Carcinoma Stages T1 Versus T2a: Prospective Comparative Study.

NCT05486871

Renal Cell Carcinoma

UNKNOWN NA

Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for AGC

NCT03708783

Gastric Cancer Gastrectomy Laparoscopic Surgery +1 more

UNKNOWN NA

Complete Mesogastric Excision With D2 Lympadenectomy for Gastric Cancer:

NCT06281379

Gastric Cancer Gastric Neoplasm Gastric Cancer Stage

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

From November 2009 to August 2018 a total of 292 patients who underwent LPN by global ischemia were included in the study. The patients were allocated into two groups according to the tumor size; T1a (≤ 40 mm, n=215), T1b (41-70 mm, n=77). Demographics features, clinical tumor characteristics, intraoperative and postoperative outcomes were analyzed. A negative surgical margin, warm ischemia time (WIT) \< 20 min and no postoperative complications (Clavien-Dindo ≥ grade 3) were accepted to achieve the trifecta outcomes. Pentafecta has defined as trifecta criteria plus \>90% preservation of estimated glomerular filtration rate (eGFR) and no stage upgrade of chronic kidney disease 12 months after LPN. Univariable and multivariable analysis were used to identify factors predicting trifecta and pentafecta achievement.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Cancer Renal Neoplasm Renal Cell Carcinoma Surgery Surgery--Complications Renal Functional Abnormality Oncology Oncology Problem Kidney Ischemia Kidney Injury Urologic Neoplasms Urologic Cancer Kidney Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Functioning contraleteral kidney
* Patients with complete data
* Patients with single renal tumor on the effected side
* Patients who approved the written consent form

Exclusion Criteria

* The patients with bilateral renal tumors (n=8, 16 LPNs)
* solitary kidney (n=8)
* horseshoe kidney (n=4)
* pelvic ectopic kidney (n=2)
* graft kidney (n=2)
* those with multiple renal tumors in a single kidney (n=3) or with \> 7 cm renal tumor (n=6)
* Patients who were operated on for colon cancer (n=4), prostate cancer (n=2), endometrial cancer (n=1) or adrenal mass (n=2) within the first year after LPN

Minimum Eligible Age

18 Years

Maximum Eligible Age

82 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No